Abstract
When fully suppressive regimens are not available, incompletely suppressive regimens also provide immunologic benefits. In this study, with stable background therapy, human immunodeficiency virus (HIV)-infected patients who were randomized to receive atazanavir or boosted atazanavir, compared with those who continued boosted protease inhibitor therapy, maintained similar virologic and immunologic control, resistance-mutation patterns, and replication capacities with reduced use of lipid-lowering medication.
Publication types
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adult
-
Anti-HIV Agents / therapeutic use*
-
Atazanavir Sulfate
-
CD4 Lymphocyte Count
-
CD4-Positive T-Lymphocytes / immunology
-
Drug Resistance, Viral
-
Female
-
HIV / drug effects*
-
HIV Infections / drug therapy*
-
HIV Infections / immunology*
-
HIV Infections / virology
-
HIV Protease Inhibitors / therapeutic use*
-
HIV-1 / physiology
-
Humans
-
Male
-
Middle Aged
-
Oligopeptides / therapeutic use
-
Pyridines / therapeutic use
-
Viremia*
-
Virus Replication
Substances
-
Anti-HIV Agents
-
HIV Protease Inhibitors
-
Oligopeptides
-
Pyridines
-
Atazanavir Sulfate